Chinese Cell Therapy Firm JW Therapeutics Closes $90 Million Series A Financing

Login to View

Chinese cell therapy company JW Therapeutics (Shanghai) Co., Ltd announced that it has raised a US$90 million series A found led by investors Temasek, Sequoia Capital China, and YuanMing Capital, a Beijing-based US dollar fund focusing on investments in pharmaceutical research and development, medical devices and services in both China and the U.S.

Continue reading with a China Money Network subscription

Join Now

Already have an account or paid subscription? Log in